Is AUTL above its 150-day moving average?

AUTL is currently above its 150-day moving average by 22.58%. The MA150 sits at $1.53.

What is AUTL's RSI right now?

AUTL's 14-period RSI is 64.8. This is in a neutral zone (30–70).

Is AUTL's MACD bullish or bearish?

AUTL's MACD histogram reads +0.0147. A positive histogram means short-term momentum is leaning bullish.

How are AUTL's technical signals calculated?

Scanance computes AUTL's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

AU

Autolus Therapeutics plc

AUTLHealthcareNASDAQ

Biotechnology

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot · Today

Premium

Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →

Financials · Annual

Revenue

$75.4M

+644.9% YoY

Net Income

-$287.5M

-30.3% YoY

EBITDA

-$239.1M

-18.3% YoY

Scan Results

Daily timeframe

DateIndicatorDetails

About Autolus Therapeutics plc

Part of the healthcare sector, Autolus Therapeutics plc (AUTL) is listed under Biotechnology. Valued at $497.7M, AUTL is a small-cap name in its sector. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Key stats

Market Cap$497.7M

Fwd P/E-2.96

EPS$-1.09

52W Change-2.1%

ROE-29.6%

Analysis

Autolus Therapeutics plc reports $217.4M in cash and $0 in total debt. ROE of -29.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $6.2M (2022) to $75.4M (2025), reflecting a 1117% increase over the period.

As with any equity investment, AUTL carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Autolus Therapeutics plc and its sector.

Links

Company website ↗

Autolus Therapeutics plc

News & analytics is part of Premium.

Technical readouts are part of Premium.